Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

NCT07465926 is registered in ClinicalTrials.gov with Chung Shan Medical University as lead sponsor.

NCT NCT07465926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07465926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation
Lead sponsor
Chung Shan Medical University
Phase
Observational
Overall status
Completed
Start date
January 1, 2017
Completion date
January 31, 2026
Enrollment
451,036 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease risk factor, cardiovascular-kidney-metabolic syndrome, kidney disease, obesity & overweight, type 2 diabetes